001052211 001__ 1052211
001052211 005__ 20260122203307.0
001052211 0247_ $$2doi$$a10.1016/j.radonc.2024.110594
001052211 0247_ $$2ISSN$$a0167-8140
001052211 0247_ $$2ISSN$$a1879-0887
001052211 0247_ $$2datacite_doi$$a10.34734/FZJ-2026-00839
001052211 037__ $$aFZJ-2026-00839
001052211 082__ $$a610
001052211 1001_ $$00000-0001-8871-4654$$aBaumert, Brigitta G.$$b0$$eCorresponding author
001052211 245__ $$aESTRO-EANO guideline on target delineation and radiotherapy for IDH-mutant WHO CNS grade 2 and 3 diffuse glioma
001052211 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2025
001052211 3367_ $$2DRIVER$$aarticle
001052211 3367_ $$2DataCite$$aOutput Types/Journal article
001052211 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1769087335_22507
001052211 3367_ $$2BibTeX$$aARTICLE
001052211 3367_ $$2ORCID$$aJOURNAL_ARTICLE
001052211 3367_ $$00$$2EndNote$$aJournal Article
001052211 500__ $$aNo funding has been received for the development of these guidelines.
001052211 520__ $$aPurpose: This guideline will discuss radiotherapeutic management of IDH-mutant grade 2 and grade 3 diffuse glioma, using the latest 2021 WHO (5th) classification of brain tumours focusing on: imaging modalities, tumour volume delineation, irradiation dose and fractionation.Methods: The ESTRO Guidelines Committee, CNS subgroup, nominated 15 European experts who identified questions for this guideline. Four working groups were established addressing specific questions concerning imaging, target volume delineation, radiation techniques and fractionation. A literature search was performed, and available literature was discussed. A modified two-step Delphi process was used with majority voting resulted in a decision or highlighting areas of uncertainty.Results: Key issues identified and discussed included imaging needed to define target definition, target delineation and the size of margins, and technical aspects of treatment including different planning techniques such as proton therapy.Conclusions: The GTV should include any residual tumour volume after surgery, as well as the resection cavity. Enhancing lesions on T1 imaging should be included if they are indicative of residual tumour. In grade 2 tumours, T2/FLAIR abnormalities should be included in the GTV. In grade 3 tumours, T2/FLAIR abnormalities should also be included, except areas that are considered to be oedema which should be omitted from the GTV. A GTV to CTV expansion of 10 mm is recommended in grade 2 tumours and 15 mm in grade 3 tumours. A treatment dose of 50.4 Gy in 28 fractions is recommended in grade 2 tumours and 59.4 Gy in 33 fractions in grade 3 tumours. Radiation techniques with IMRT are the preferred approach.Keywords: Anaplastic glioma; Delineation; IDH-mutant diffuse glioma; Low grade glioma; Radiotherapy; Target volume.
001052211 536__ $$0G:(DE-HGF)POF4-5252$$a5252 - Brain Dysfunction and Plasticity (POF4-525)$$cPOF4-525$$fPOF IV$$x0
001052211 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
001052211 7001_ $$0P:(DE-HGF)0$$aP. M. Jaspers, Jaap$$b1
001052211 7001_ $$00000-0001-8699-3506$$aKeil, Vera C.$$b2
001052211 7001_ $$0P:(DE-Juel1)143792$$aGalldiks, Norbert$$b3
001052211 7001_ $$00000-0001-7550-1326$$aIzycka-Swieszewska, Ewa$$b4
001052211 7001_ $$0P:(DE-HGF)0$$aTimmermann, Beate$$b5
001052211 7001_ $$00000-0003-2255-2255$$aGrosu, Anca L.$$b6
001052211 7001_ $$00000-0003-1239-1603$$aMinniti, Giuseppe$$b7
001052211 7001_ $$00000-0003-4406-7621$$aRicardi, Umberto$$b8
001052211 7001_ $$0P:(DE-HGF)0$$aDhermain, Frédéric$$b9
001052211 7001_ $$0P:(DE-HGF)0$$aWeber, Damien C.$$b10
001052211 7001_ $$0P:(DE-HGF)0$$avan den Bent, Martin$$b11
001052211 7001_ $$0P:(DE-HGF)0$$aRudà, Roberta$$b12
001052211 7001_ $$0P:(DE-HGF)0$$aNiyazi, Maximilian$$b13
001052211 7001_ $$0P:(DE-HGF)0$$aErridge, Sara$$b14
001052211 773__ $$0PERI:(DE-600)1500707-8$$a10.1016/j.radonc.2024.110594$$gVol. 202, p. 110594 -$$p110594 -$$tRadiotherapy and oncology$$v202$$x0167-8140$$y2025
001052211 8564_ $$uhttps://juser.fz-juelich.de/record/1052211/files/PDF.pdf$$yOpenAccess
001052211 909CO $$ooai:juser.fz-juelich.de:1052211$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
001052211 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)143792$$aForschungszentrum Jülich$$b3$$kFZJ
001052211 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5252$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
001052211 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-07
001052211 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-07
001052211 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-01-07
001052211 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-01-07
001052211 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-01-07
001052211 915__ $$0LIC:(DE-HGF)CCBYNCND4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
001052211 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bRADIOTHER ONCOL : 2022$$d2025-01-07
001052211 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-07
001052211 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-07
001052211 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
001052211 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-01-07
001052211 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bRADIOTHER ONCOL : 2022$$d2025-01-07
001052211 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-07
001052211 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-07
001052211 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2025-01-07$$wger
001052211 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-07
001052211 920__ $$lyes
001052211 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
001052211 980__ $$ajournal
001052211 980__ $$aVDB
001052211 980__ $$aUNRESTRICTED
001052211 980__ $$aI:(DE-Juel1)INM-3-20090406
001052211 9801_ $$aFullTexts